Background Most children with medulloblastoma fall within the standard-risk clinical disease group defined by absence of high-risk features (metastatic disease, large-cell/anaplastic histology, and MYC amplification), which includes 50-60% of patients and has a 5-year event-free survival of 75-85%. Within standard-risk medulloblastoma, patients in the WNT subgroup are established as having a favourable prognosis; however, outcome prediction for the remaining majority of patients is imprecise. We sought to identify novel prognostic biomarkers to enable improved risk-adapted therapies.
Introduction
Medulloblastoma, the most common malignant child hood brain tumour, is now recognised as an umbrella term for different molecular pathological disease entities. These entities differ in their progenitor cells, charac teristic mutations, biological profiles, and clinical behaviour. Currently, WHO classification of CNS tumours recog nises four distinct genetically defined entities (WNT, SHHTP53 wildtype , SHHTP53 mut , and nonWNT/nonSHH). 1 NonWNT/nonSHH medullo blastoma encompasses Group3 and Group4, which were defined by epigenetic and mRNA expression signatures 2 and are considered provisional variants by the 2016 WHO classification. 1 Understanding the molecular pathology and clinical relevance of medulloblastoma subtypes provides sub stantial opportunities for personalised riskadapted therapies.
Discovery and validation of clinically meaningful medullo blastoma features in previous clinical trial cohorts have driven advances in the clinical management of the disease. Children younger than 16 years of age at diagnosis with WNTactivated medulloblastomas have
Research in context
Evidence before this study International consensus and the 2016 WHO classification recognise the following distinct clinico-molecular disease entities in medulloblastoma: WNT, SHH-TP53 wild-type , SHH-TP53 mut , and non-WNT/non-SHH (encompassing Group3 and Group4). Standard-risk, non-infant disease (with 75-85% 5-year progression-free survival and affecting 50-60% of patients) represents the largest clinical treatment group of patients. The ongoing pan-European SIOP PNET 5 MB clinical trial defines standard-risk, non-infant disease as the absence of high-risk clinical features such as metastatic disease or subtotal resection, molecular features (MYC or MYCN amplification or TP53 mutation in SHH medulloblastoma), and histological characteristics (large-cell/anaplastic disease). These definitions were established based on previous disease-wide studies. The SIOP PNET 5 MB trial is investigating reduced-intensity therapies for patients classified as standard-risk with expected good prognosis (ie, WNT medulloblastoma), aimed at maintaining overall survival while minimising late toxicities. However, biomarkers that stratify risk within remaining standard-risk patients with non-WNT medulloblastoma have not been identified. Moreover, novel non-WNT/non-SHH medulloblastoma epigenetic subtypes have been recognised; however, these subtypes remain to be validated and implemented clinically. Our own reviews of the literature formed the foundation for the present study; we did not carry out any formal literature searches before the study start date (December, 2015) .
Added value of this study
To our knowledge, HIT-SIOP PNET 4 is the only completed pan-European clinical trial in patients with standard-risk medulloblastoma. However, to date, systematically collected biological material remaining from this trial was not amenable to contemporary molecular analysis. Application of novel methods to enable assessment of this cohort, and investigation of an independent demographically matched standard-risk medulloblastoma validation cohort, allowed derivation and validation of biomarker-driven, risk-stratification models on the basis of the molecular pathology of standard-risk medulloblastoma, including a novel whole chromosomal cytogenetic aberration signature within standard-risk non-WNT/non-SHH medulloblastoma. These newly described whole chromosomal cytogenetic aberration signatures allowed reallocation of more than 50% of HIT-SIOP PNET 4 patients with standard-risk medulloblastoma into a favourable-risk group, while the remaining patients were classified as high risk. Therefore, findings from this study resolve current patients with standard-risk medulloblastoma into biomarker-defined distinct favourable-risk and high-risk groups, and represent a substantial step in our ability to risk stratify and clinically manage medulloblastoma.
Implications of all the available evidence
The results of this study redefine the concepts of risk stratification in standard-risk medulloblastoma, providing insight into its molecular subtypes, their underpinning biology, and clinical application. Stratification of standard-risk medulloblastoma by use of the biomarkers and validated schemes we describe could allow assignment of 150-200 patients per year in Europe into a favourable-risk group, and such patients could benefit from reduction of treatment intensity. Patients not classified as favourable-risk should be considered high-risk and might benefit from treatment intensification. The molecular risk groups and biomarker schemes presented in this study are amenable to routine diagnostic assessment and provide a foundation for future clinical trials and research investigations.
consistently achieved favourable outcomes (5year event free survival >95%), 3, 4 whereas other disease features, including MYC or MYCN amplification, largecell/ anaplastic histology, metastatic disease, or subtotal resection, define highrisk disease (5year eventfree survival <60%). 5 These disease features now under pin riskadapted therapies in ongoing biomarkerdriven international prospective clinical studies, such as the SIOP PNET 5 MB (NCT02066220) and SJMB12 (NCT01878617) trials, which aim to improve outcomes through reducedintensity therapies for favourablerisk patients and randomised assessment of adapted therapies in the remaining patients.
Standardrisk medulloblastoma represents the pre dominant clinical treatment group (around 60% of patients) and is defined by the absence of clinical, molecular, and histopathological highrisk features. This group encompasses tumours of all variants except high risk SHHTP53 mut .
6,7 Diagnosis of favourablerisk, WNT disease (around 20% of patients with standardrisk medulloblastoma) provides a clear precedent for therapy deescalation within clinical trials. By contrast, patients with nonWNT, standardrisk medullo blastoma have heterogeneous outcomes (5year eventfree survival around 75%), and further actionable risk groups are yet to be identified or validated to the point of clinical application. The favourable risk of patients with standardrisk, SHH TP53 wildtype medulloblastoma 6, 7 identified in retrospective series requires validation in clinical trials, and reproducible and clinically significant molecular pathological features with in nonWNT/nonSHH tumours remain to be defined. Research has found that Group3 and Group4 medulloblastomas represent heterogeneous, bio logically overlapping entities-few recurrent mutations have been observed, whole chromosomal cytogenetic aberrations are common, [8] [9] [10] [11] and evidence of novel molecular subtypes is emerging. 6, 12, 13 To our knowledge, HITSIOP PNET 4 14 is the first completed, international, prospective clinical trial of nonmetastatic childhood medulloblastoma (patients aged 4-21 years at diagnosis) and this cohort of patients represents a unique opportunity to explore the molecular pathology of standardrisk medulloblastoma, its potential for risk stratification, and the development of new thera peutic concepts. Trial participants were post operatively staged and randomly assigned to treat ment with standard or hyperfractionated radio therapy, followed by chemo therapy with eight cycles of cisplatin, lomustine, and vincristine. No difference in eventfree survival was observed between the two treatment groups. 14 Formalinfixed, paraffinembedded (FFPE) tumour material for biological studies was prospectively collected, which enabled confirmation of favourable outcomes in patients with WNT medulloblastoma (defined by immuno histochemistry [IHC] ) and identification of chromosome 17 imbalances on a diploid background (17p loss and/or 17q gain, by fluorescence insitu hybridisation [FISH] ) as a marker of poor prognosis. 15 However, until now, contemporary molecular character isation of the HITSIOP PNET 4 cohort, and assessment of its clinical relevance, has been restricted by the low quality and quantity of remaining tumour material.
In this Article, we report comprehensive molecular and pathological characterisation of the HITSIOP PNET 4 cohort using novel technologies 16, 17 developed and adapted for assessment of the remnant tumour material. This analysis, alongside an independent, demo graphically matched, standardrisk medullo bla stoma validation cohort, enabled the discovery and validation of concerted whole chromosomal aberration signatures with prognostic value for patients with nonWNT/non SHH medulloblastoma. We describe the development of risk stratifi cation models for standardrisk, nonWNT/ nonSHH disease, which might allow reassignment of all patients with standardrisk medulloblastoma into biomarkerdefined favourablerisk or highrisk groups.
Methods

Study design and participants
In this retrospective analysis, we assessed remaining tumour samples from patients from the HITSIOP PNET 4 trial (NCT01351870).
14 Between Jan 1, 2001, and Dec 31, 2006, 338 patients were recruited from 120 different treatment centres in seven European countries (France, Germany, Italy, the Netherlands, Spain, Sweden, and the UK; appendix p 3). The study investigated treatment outcomes in patients aged 4-21 years using either hyperfractionated radiotherapy or standard delivery radiotherapy followed by chemo therapy. 1 Standard delivery radiotherapy comprised 23·4 Gy to the craniospinal axis and 54 Gy to the whole posterior fossa, and was given over 42 days in 30 fractions of 1·8 Gy each day for 5 days per week. Hyperfractionated radiotherapy was given in 68 fractions at 1·0 Gy twice per day with an 8 h interval between fractions, given over 48 days. The total craniospinal dose was 36 Gy, and the whole posterior fossa dose was 60 Gy, with a further boost to 68 Gy to the tumour bed. Adjuvant chemotherapy was started 6 weeks after the end of radiotherapy. Eight cycles of cisplatin (70 mg/m² intravenously) and lomustine (75 mg/m²) on day 1, and vincristine (1·5 mg/m² intravenously) on days 1, 8, and 15, were given with a 6 week interval between each cycle. 14 Minute remnant material (cytospinconcentrated cellular nuclei preparations) or tumour sections, origi nally intended for FISH and IHC, 15 were available for analysis (samples from 147 patients). We retained tumours from patients with subtotally resected disease 18 or categorised as MYCNamplified to assess their prognostic value in a clinically controlled cohort. 6, 11, 15 We excluded MYC-amplified tumours because of their established poor prognosis. 5 136 tumour samples met these criteria and underwent molecular investigation. Written informed consent for tumour collection for biological studies was obtained from patients or their parents. Tumour investi gations were done with approval from Newcastle and North Tyneside Research Ethics Committee (study reference 07/Q0905/71)-all tumour material was collected in accordance with this approval.
Procedures
Because only material of mostly low quantity and quality was available, the HITSIOP PNET 4 samples were unsuitable for sub group assessment using conventional approaches (DNA methylation array 19 or mRNA expres sion analysis by Nanostring 20 ); therefore, we analysed all samples using a mass spectrometryminimal methylation classifier (MSMIMIC) assay to assess their molecular subgroup. 16 For the validation cohort, samples were of sufficient quality and quantity to do Illumina 450k DNA methylation microarray (62 DNA samples were from frozen material and eight were from FFPE tissue) and consensus methylation subgroup was assigned as described previously. 6 We assessed amplification of MYC and MYCN onco genes by interphase FISH 15 and estimated gene copy numbers from molecular inversion probe and DNA methylation arrays, 19 as previously described. We analysed mutations in exons 4-9 of TP53 and exon 3 of CTNNB1 with Sanger sequencing as previously described. 21 We assessed mutations in APC using a customised next generation DNA sequencing panel (Illumina; San Diego, CA, USA) in samples with CTNNB1 wildtype WNT medulloblastoma. We used a molecular inversion probe array (335 000 inversion probes; version 2.0; Affymetrix; Santa Clara, CA, USA) to identify aberrant changes in genomic copy number in samples from the HITSIOP PNET 4 trial. 17 Raw molecular inversion probe data were analysed using Nexus Copy Number 7.0 Discovery Edition (BioDiscovery; El Segundo, CA, USA). We used SNPFASST2 segmen tation algorithm to make copy number and loss of heterozygosity estimations. We used GISTIC (Genomic Identification of Significant Targets in Cancer, v 1.0) to identify focal chromosomal aberrations (appendix pp 10-12). 22 We analysed the validation cohort samples on the Illumina 450k DNA methylation micro array (Illumina; San Diego, CA, USA), and estimated chromosomal and focal copy number changes by use of the R package conumee v 1.13.0, as previously described. 6 We defined a whole chromosomal aberration group of patients by hier archical clustering of recurrent (ie, >15%) aberrations.
Eventfree survival was defined as the time from surgery to first event (progression or relapse), or date of last followup. Patients whose followup time exceeded 10 years were rightcensored at 10 years. Clinical follow up data were collected according to the HITSIOP PNET 4 trial protocol.
14 For the validation cohort, clinical data were collected in the same format from individual treatment centres.
Statistical analysis
Using hierarchical clustering, we clustered samples classified as nonWNT/nonSHH medulloblastoma sub type by their recurrent whole chromosomal aberration (ie, incidence >15%; appendix p 2). After molecular sub grouping, we observed similar cytogenetic changes and eventfree survival between the nonWNT/nonSHH medullo blastomas subclassified as Group3 and Group4 (appendix p 9). Because of these results and the emerging evidence of their shared biology, 6, 12 we considered these groups together in subsequent eventfree survival analyses.
To test the null hypothesis that eventfree survival was not associated with clinical, molecular, or patho logical variables in patients with Group3 or Group4 medullo blastoma, we constructed KaplanMeier curves and compared patient groups with logrank tests.
Using , and cumulative numbers of total whole chromosomal aber rations (gains vs losses). We verified the pro portionality assumption for Cox modelling using scaled Schoenfeld residuals. We derived pragmatic assignments of patient risk by combining whole chromosomal aberrations that were significantly different in univariate testing to define risk groups and assessed their predictive value by calcu lating total area under the curve (AUC), sensitivity, and specificity at 5 years since diagnosis (appendix p 2). We clustered the tumour samples from the validation cohort by the recurrent whole chromosomal aber rations previously identified in the HIT SIOP PNET 4 trial standardrisk, nonWNT/nonSHH medulloblastoma cohort and validated the derived risk stratification schemes.
Finally, to better understand the nature of the identified risk groups, we classified the validation cohort according to the recently published refinements of epigenetically defined substructures within non WNT/nonSHH medullo blastoma. 6, 12 Validation cohort samples were assigned to subgroup variants according to these published studies and visualised using tdistributed stochastic neighbour embedding (appendix pp 2-3).
We set the significance threshold at p<0·05 for all statistical tests in this study, and twotailed p values are reported. We assessed significance of association using Fisher's exact test, and visualised the strength of asso ciations using χ² test residuals.
Further detailed methods are provided in the appendix pp 1-3. Statistical and bio informatic analyses were done with R (version 3.4.2).
Role of the funding source
The funders of the study had no role in study design, data collection, data analysis, data interpretation, or writing of the report. The corresponding author had full access to all the data in the study and had final responsibility for the decision to submit for publication. [8] [9] [10] [11] as anticipated following exclusion of children younger than 4 years, adults older than 21 years, and patients with highrisk or metastatic disease from this cohort.
The prognostic relevance and demographic distribution of key clinical features across the study cohorts were compatible with our previous reports of the entire HITSIOP PNET 4 trial (table). 14, 15 With a median followup of 6·7 years (IQR 5·6-8·4) in the HITSIOP PNET 4 cohort, 5year eventfree survival was equivalent between patients who received standard radiotherapy and those who received hyperfractionated 4 (58) 6 (54) 63 (2) 61 (0) 57 (2) 50 (4) 38 (22) 35 (19) 14 (44) 18 ( (0) 9 (102) 1 (6) 111 (2) 8 (0) 98 (5) 5 (1) 67 (37) 4 (2) 31 ( radiotherapy (hazard ratio [HR] 0·81, 95% CI 0·36-1·82; p=0·61; figure 2), while patients who had a subtotal resection had a poorer eventfree survival at 5 years than those who underwent gross total resection (HR 3·18, 1·08-9·37; p=0·036; figure 2). We found no differences in terms of 5year eventfree survival between the four methylation subgroups (figure 2; WNT 5year eventfree survival 88·5%, 95% CI 77·0-100; Group4 5year eventfree survival 81·6%, 73·3-90·8; Group3 5year eventfree survival 80·0, 62·1-100; SHH 5year eventfree survival 75·3%, 56·9-99·6; WNT vs Group4 HR 0·61, 95% CI 0·18-2·12, p=0·44; SHH vs Group4 1·27, 0·42-3·86, p=0·68; Group3 vs Group4 1·13, 0·32-3·94, p=0·85). Group3 and Group4 had very similar eventfree survival curves ( figure 2 ). By contrast, we found a significant association between the presence of whole chromosomal aberrations and favourable eventfree survival outcomes compared with the absence of whole chromosomal aberrations (HR 4·05, 95% CI 1·79-9·13; p=0·00077; figure 2). We investigated the clinical, molecular, and eventfree survival characteristics of WHOdefined medullo blastoma molecular entities in the HITSIOP PNET 4 cohort. (1) 4 (5) 46 (19) 2 (7) 18 ( (0) 3 (46) 3 (28) 50 (0) 34 (0) 45 (1) 28 (0) 29 (17) 21 (7) 14 (32) 6 (22) 11 showed significantly worse eventfree survival for patients in this cohort (p=0·00067; appendix pp 7-8).
The 91 (67%) nonWNT/nonSHH tumours in the HIT SIOP PNET 4 cohort of 136 were characterised by a higher incidence of whole chromo somal aberrations (eg, chromosome 7 gain, and chromosome 8 figure 1 ; appendix pp 11-12). Moreover, previously reported prognostic factors (MYCN amplification, i17q alterations, and sub total resection) 11, 18 were not associated with worse eventfree survival (figure 2; appendix p 15), while the observed cohortwide prognostic significance of whole chromosomal aber rations was maintained in this subgroup (figure 2).
We next investigated whether the observed mole cular heterogeneity within the 91 nonWNT/nonSHH medullo blastoma tumours could inform its biological basis and clinical behaviour. Through unsupervised hierarchical cluster analysis of recurrent whole chromo somal aberrations, we identified two clinically and biologically distinct subgroups of tumours (figure 3). The first cytogenetic group was strongly associated with a pattern of i17q in isolation, diploid karyotypes, few recurrent whole chromosomal aberrations, and more relapses (p=0·00084). The second cytogenetic group was char acterised by a spectrum of multiple recurrent and co incident whole chromosomal aberrations (figure 3) and aneuploidy (p<0·0001; appendix p 13), and was associated with fewer relapses.
Whole chromosomal aberrations within nonWNT/ nonSHH medulloblastoma samples were associated with improved 5year eventfree survival (figure 4). 55 (60%) of 91 nonWNT/nonSHH tumours had multiple recurrent and coincident whole chromo somal aberrations and showed favourable outcomes compared with those without whole chromosomal aberrations (HR 0·16, 95% CI 0·05-0·50; p=0·0015; figure 4). The total number of whole chromosomal aberrations in a given tumour was prognostic for eventfree survival. When different whole chromosomal aberration numbers were assessed, timedependent AUC analysis identified 0 versus 1 or more recurrent whole chromosomal losses as the best discri minator of outcome (figure 4; appendix p 14). However, eventfree survival was not only dependent on the total numbers of whole chromosomal aberrations. Analysis of the prognostic effect of specific whole chromosomal aberrations in individual chromo somes showed that chromosome 7 gain (HR 0·15, 95% CI 0·04-0·51, p=0·0025), chromosome 8 loss (HR calculation not possible because of group with no events; p=0·0014 for logrank test), and chromosome 11 loss (HR 0·10, 95% CI 0·01-0·79, p=0·029) represented the most significant specific whole chromo somal aber rations (appendix pp [15] [16] .
Through assessment of eventfree survival models for nonWNT/nonSHH medulloblastoma sam ples within the HITSIOP PNET 4 cohort, we identified at least two of the following-chromosome 7 gain, chromosome 8 loss, and chromosome 11 loss-as the optimally performing risk stratification scheme (appendix pp [14] [15] , outperforming other cytogenetic schemes and trialbased models, such as the SIOP PNET 5 MB trial model, in this patient group (figure 4; appendix p 14). This model, based on combinations of chromosome 7 gain, chromosome 8 loss, and chromosome 11 loss, stratified 38 (42%) of 91 nonWNT/nonSHH medullo blastomas as being favour able risk, with a 5year eventfree survival of 100%, (vs 68%, 95% CI 56·5-81·7 for highrisk tumours; 3 (51) 3 (23) 55 (0) 29 (0) 50 (1) 23 (0) 32 (20) 20 (4) 13 (38) 7 ( (0) 3 (45) 3 (29) 47 (0) 37 (0) 44 (1) 29 (0) 30 (16) 22 (8) 13 ( (1) 25 (14) 29 (10) 9 (29) 12 ( 3 (19) 4 (32) 17 (2) 36 (6) 15 (4) 22 (12) 11 (8) 15 (18) 6 (13) (68) 55 (2) 82 (6) 53 (4) 57 (13) 36 (22) 42 (28) 15 (42) with findings from the overall HITSIOP PNET 4 trial cohort (data not shown). 14 We tested the reproducibility of our findings in an independent cohort of 70 nonWNT/nonSHH medullo blastomas, which matched the clinical and demographic characteristics of our HITSIOP PNET 4 standardrisk medulloblastoma cohort, collected from 1990 to 2014 (table, figure 5 ). The median eventfree survival for these patients was 5·6 years (IQR 3·1-8·1).
The characteristics, incidence, and associated event free survival outcomes of the identified whole chromo somal aberrationdefined subgroups were recapitulated (figure 5; appendix p 17). Our proposed whole chromo somal aberration signaturebased model represented the best performing risk stratification scheme (figure 5; appendix p 18). The favourablerisk whole chromosomal aberration signature, defined by chromo some 7 gain, chromosome 8 loss, and chromo some 11 loss, was observed within multiple novel methylation subgroups, and was significantly associated with MB Group4LowRisk 6 and Group3 and Group4 subtypes VI and VII 12 (p<0·0001, appendix p 18). By contrast, the highrisk group was significantly associated with MB Group4HighRisk 6 and subtype VIII 12 (p<0·0001, figure 5 ; appendix p 18). When we considered our eventfree survival models in Group4 patients alone, we found equivalent prognostic relation ships in both the HITSIOP PNET 4 and validation cohorts (appendix pp 14, [19] [20] .
A pooled analysis applied the validated whole chromo somal aberration signaturebased riskstratification model to the merged nonWNT/nonSHH medullo blastomas from the HITSIOP PNET 4, and validation cohorts (n=161) and classified 58 (36%) nonWNT/ nonSHH medulloblastomas as favourablerisk and 103 (64%) as highrisk; 5year eventfree survival was 98·3% (95% CI 94·9-100) in the favourablerisk group vs 64% (52·9-73·2) in the highrisk group (HR 25·09, 95% CI 3·44-183·20; p=0·0015; figure 5). Together with established favourablerisk WNT medullo blastomas in patients younger than 16 years (20 [15%] of 136 patients; appendix pp 5-6) and TP53 wildtype SHH medulloblastomas (11 [8%] of 136 tumours; appendix pp 7-8), these newly identified chromosomal signatures identified 69 (51%) of 134 (two SHH tumours had unknown TP53 status and were therefore excluded from the calculation) molecularly characterised patients with medulloblastoma from the HITSIOP PNET 4 cohort with a favourable prognosis (5year eventfree survival of 100%).
Discussion
Implementation of enabling technologies (MSMIMIC and molecular inversion probe assay) allowed us to systematically assess the molecular pathology of the standardrisk medulloblastoma clinical group within the HITSIOP PNET 4 patient cohort. To our knowledge, no equivalent multicentre, prospective investigations of standardrisk medulloblastoma have been reported. Although wider, retrospective medulloblastoma datasets are available, these typically lack the full clinical and molecular annotation necessary to define the standard risk medulloblastoma group. The standardrisk medullo blastoma group displayed distinct demographics versus diseasewide cohorts. [8] [9] [10] [11] WNT and Group4 sub groups were enriched within the standardrisk medulloblastoma cohorts because of the absence of clinicomolecular highrisk features in standardrisk disease.
The favourable prognosis of patients with WNT medulloblastoma was confirmed in patients from the HITSIOP PNET 4 cohort who were younger than 16 years at diagnosis. However, patients older than 16 years did not share this good prognosis, consistent with previous reports. 15, 23 Together, these data do not support therapy deescalation in patients with WNT medulloblastoma older than 16 years of age. Patients with SHH medulloblastoma without TP53 muta tions (SHHTP53 wildtype ) or chromo some 17p loss similarly had a favourable prognosis. These data validate independent previous findings 6, 7 and support the eligibility of these patients for deescalated or targeted therapies (eg, SMO inhibitors). 24 Development of biomarkerdriven treatment strategies for the large remaining group of patients with nonWNT/ nonSHH disease represents the largest ongoing chal lenge for standardrisk medulloblastoma. In the absence of highrisk features, 5 these patients had a 5year event free survival of 81% (95% CI 74-90) in the HITSIOP PNET 4 trial. As described in this Article, nonWNT/non SHH medulloblastoma tumours have few recurrent mutations, and structural chromosomal abnor malities are the most common genomic features. [8] [9] [10] When comparing Group4 and Group3 tumours, we found around 90% overlap of chromosomal alterations between the two subgroups and equivalent eventfree survival. Coupled with evidence supporting their shared under lying biological mechanisms, 6, 12 we considered Group3 and Group4 tumours together in our analysis. We identified two biologically and clinically distinct non WNT/nonSHH medulloblastoma groups. The first group was a cytogenetically quiet, highrisk group associated with diploid genomes, many with i17q as the sole defining genomic feature. These tumours provide a wider biological context for the poorrisk group of patients with nonWNT disease with chromosome 17p or q defects in a diploid background (chr17(im)/diploid(cen)), previously identified by interphase FISH in this cohort. 15 The second group was large and defined by multiple, cooccurring whole chromosomal aber rations, common polyploidy, and improved relative outcomes.
In this whole chromosomal aberration group, using multivariable eventfree survival analysis and risk modelling, we deduced a whole chromosomal aberration signature (two or more of chromosome 7 gain, chromo some 8 loss, and chromosome 11 loss), which best defined patients with nonWNT/nonSHH medulloblastoma with routine molecular diagnostic practice and, following their validation in independent clinically controlled and biomarkerdefined cohorts, could form the basis of international clinical trials aimed at improving outcomes.
In summary, our molecular pathological character isation of the HITSIOP PNET 4 cohort identified and inde pendently validated a whole chromosomal aber ration signaturedefined subgroup of nonWNT/nonSHH medullo blastomas associated with good prognosis. Combination of these newly defined subtypes with the favourablerisk WNT and SHH medulloblastomas validated in our study redistributed around 50% of patients with standardrisk medulloblastoma into a favourablerisk group, who could benefit from reducedintensity therapies aimed at maintaining overall survival while reducing treatmentassociated toxicities and late effects. Patients not classified into this favourablerisk group had a 5year eventfree survival of around 60% and should be considered high risk. In the HITSIOP PNET 4 cohort, this model compared favourably with published and currently accepted risk stratification schemes (eg, Shih and colleagues 11 and SIOP PNET 5 MB; 5 appendix p 14) and redefines our understanding of biomarkers and disease risk within the previously clinically defined standardrisk medulloblastoma patient group.
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FD received personal fees from BristolMyers Squibb, Tesaro Oncology, Servier, and Celgen. SR received grant funding from the German Children's Cancer Foundation (Deutsche Kinderkrebsstiftung). All other authors declare no competing interests. favourable prognosis. We validated these findings in an independent demographically matched standardrisk medulloblastoma cohort, and they were reproducible when Group4 patients were considered in isolation. This whole chromosomal aberration signature was detected within a number of novel methylation subgroups within nonWNT/nonSHH medulloblastoma, and associated with the lowrisk MB Group4LowRisk , 6 and Group3 and Group4 subtypes VI and VII. 12 By contrast, the highrisk isolated i17q diploid group was associated with highrisk MB Group4 HighRisk 6 and subtype VIII. 12 These associations suggest common biological phenotypes and evaluation of their relative contributions to risk stratifi cation could be investigated in future clinically controlled studies.
Biologically and clinically significant whole chromo somal phenotypes are a notable feature of childhood malignancies other than medulloblastoma. Characteristic patterns of nonrandom whole chromosomal aberrations in neuroblastoma (socalled wholechromosomal changes phenotype; more than two whole chromosomal aber rations) 25, 26 and high hyperdiploid acute lymphoblastic leukaemia (socalled highhyperdiploidy phenotype [HeH]; 51-65 chromosomes) 27 define tumour subgroups with favourable prognoses. Additionally, choroid plexus papil lomas and adult infratentorial ependymomas (posterior fossa ependymoma type B) are characterised by multiple whole chromosomal abberations. 1 Overall, whole chromosomal aberration signatures are associated with a low number of single nucleotide mutations.
This common involvement of whole chromosomal aberration signatures provides strong impetus to under stand the underlying molecular pathomechanisms, including errors in mitotic control, chromosome segre gation, and function of the spindle apparatus. Although beyond the scope of this study, investigation of associated biology (eg, geneexpression profiles, pathway involve ments, and driver events) and the involvement of specific chromosomes (ie, chromosomes 7, 8, and 11), is essential to improve understanding and therapeutic targeting. Potential opportunities include agents that target the spindle apparatus or mitotic control. For instance, vincristine (a component of medulloblastoma treatment regimens) directly targets the spindle apparatus, and the excellent whole chromosomal aberration signature associated outcomes might be explained by high sensitivity to such treatments. Indeed, the association between HeH acute leukaemia and chemosensitivity associated with increased DNA content has been long established. 28 This study has some limitations. The developed risk stratification scheme applies only to noninfant, standardrisk medulloblastoma treated with standard multimodal therapies. Children younger than 4 years, patients treated with chemotherapy only, and highrisk patients require independent assessment and develop ment of appropriate risk stratification schemes. However, our biomarkerdriven risk stratification schemes for standardrisk medulloblastoma are readily testable in
